Last reviewed · How we verify

CGT003 (E2F Duplex Decoy) — Competitive Intelligence Brief

CGT003 (E2F Duplex Decoy) (CGT003 (E2F Duplex Decoy)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Decoy oligonucleotide. Area: Oncology.

phase 3 Decoy oligonucleotide E2F transcription factors Oncology Small molecule Live · refreshed every 30 min

Target snapshot

CGT003 (E2F Duplex Decoy) (CGT003 (E2F Duplex Decoy)) — Anesiva, Inc.. CGT003 is a decoy oligonucleotide that binds and sequesters E2F transcription factors, blocking their ability to drive cell proliferation and survival.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CGT003 (E2F Duplex Decoy) TARGET CGT003 (E2F Duplex Decoy) Anesiva, Inc. phase 3 Decoy oligonucleotide E2F transcription factors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Decoy oligonucleotide class)

  1. Anesiva, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CGT003 (E2F Duplex Decoy) — Competitive Intelligence Brief. https://druglandscape.com/ci/cgt003-e2f-duplex-decoy. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: